Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2
Indoleamine 2, 3-dioxygenase 1 (IDO1) is commonly expressed by cancers as a mechanism for evading the immune system. Preclinical and clinical studies have indicated the potential of combining IDO1 inhibitors with immune therapies for the treatment of cancer, strengthening an interest in the discover...
Saved in:
Main Authors: | Sofian M Tijono (Author), Brian D. Palmer (Author), Petr Tomek (Author), Jack U. Flanagan (Author), Kimiora Henare (Author), Swarna Gamage (Author), Lukas Braun (Author), Lai-Ming Ching (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comprehensive behavioral analysis of tryptophan 2,3‐dioxygenase (Tdo2) knockout mice
by: Satoko Hattori, et al.
Published: (2018) -
Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges
by: Peng X, et al.
Published: (2022) -
Unveiling the Role of Tryptophan 2,3-Dioxygenase in the Angiogenic Process
by: Marta Cecchi, et al.
Published: (2024) -
Negative Impact of Hypoxia on Tryptophan 2,3-Dioxygenase Function
by: Frank Elbers, et al.
Published: (2016) -
Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
by: Ute F. Röhrig, et al.
Published: (2022)